Popular Articles

Obama Considers Taxing Health Benefits To Pay For Reform
As President Obama looks for a way to pay for health care reform in the United States, key Democrats advocate taxing employer-provided health benefits, The Washington Post reports.

Kaiser Daily Health Policy Report Feature Highlights Recent Blog Entries
"Blog Watch" offers readers a roundup of health policy-related blog posts.The blogosphere is buzzing about the GOP "alternative" health reform proposal from Sens. Richard Burr (N.C.), Lamar Alexander (Tenn.) and Tom Coburn (Okla.), and Reps. Devin Nunes (Calif.) and Paul Ryan (Wis.). Known as the Patients" Choice Act (.pdf), it would create state-based private health insurance exchanges and provide U.S. residents tax credits to subsidize coverage premiums. Yuval Levin of conservative stalwart The Corner calls the plan "the best comprehensive health care proposal Republicans have produced to date, and shows that at least some in the party understand the need to engage the issue with a grasp of the differences between underlying problems (like cost control) and symptoms of those problems (like access to coverage), and with an actual appreciation for economic incentives and pressures." Marguerite Higgins of the Heritage Foundation"s The Foundry says the plan "features several important conservative principles for health care reform that would allow free-market solutions to take root in the broken U.S. health care system, and give patients more decision-making power with their health care dollars."But Michael Cannon of the libertarian Cato@Liberty blog says he is "troubled" by aspects of the plan that are "self-contradictory." He writes, "On the one hand, it lists "No Tax Increases" as a core concept. Do its authors not know that imposing price controls on health insurance premiums imposes a tax on healthier-than-average consumers? And where do they think the money for "risk-adjustment" payments will come from? Heaven?" The New Republic"s Jonathan Cohn seems to agree, saying, "The details are pretty unappealing, except where there are none; and the whole thing is presented as the antithesis of big government when, in fact, it too would require at least some government intervention." Overall Cohn thinks the plan indicates good news for Democrats, concluding, "Passage of a bill seems ever more likely, to the point where potential opponents feel they must offer alternatives that embrace some of the same concepts."The Washington Post"s Ezra Klein examines the structure of the plan, calling it "the bastard child of the Massachusetts health reforms and the McCain campaign proposal." He also seems to think it"s positive news for reformers, adding, "But it"s still a step forward for the Republican Party. It"s an admission that individuals can"t go it alone. That the state has a large and important regulatory role to play. The business model of insurers is not simply broken but actively cruel. A Republican Party that accepts the principles of this plan is a Republican Party that is much likelier to accept the principles of Obama"s eventual plan." He notes that GOP leadership was not involved in the proposal.Interesting elsewhere:
News of the day
Today's Selection Of Opinions And Editorials
Health Co-ops Emerge As Weak Substitute USA Today
Oncology

Diamyd(R) Phase III Study Approved For Younger Patients In The US

Diamyd Medical reported that the company has received approval from the US Food and Drug Administration (FDA) to include children with type 1 diabetes from 10 years of age in the company"s Phase III study with the diabetes vaccine Diamyd(R). Diamyd Medical is conducting two parallel phase III studies, one in Europe and one in the USA, comprising a total of 640 patients. The objective of the studies is to evaluate the ability of the Diamyd(R) vaccine to halt or delay the autoimmune attack on the body"s insulin-producing cells, thereby preserving the body"s own ability to produce insulin in children and adolescents with recent-onset type 1 diabetes. The European study, which is being conducted in nine countries, is approved for patients between 10 and 20 years of age, whilst the US study so far has been approved only for patients 16 to 20 years, an age group with few recent-onset type 1 diabetes patients. The company is, with the new approval, allowed to begin enrollment of children from 10 years of age in the US phase III study. "This is a big step forward giving us the opportunity to accelerate patient recruitment in the US," says Elisabeth Lindner, President and CEO of Diamyd Medical. "We are pleased that the approval comes now in connection with the world"s largest diabetes conference, the ADA"s 69th Scientific Sessions, which is currently ongoing in New Orleans." The company will now, in pace with Institutional Review Board (IRB) approvals in USA, increase the number of American pediatric clinics in the study. The application for market approval is, as before, planned for spring 2011. Diamyd Medical is represented at booth #2431 at the ADA"s 69th Scientific Sessions in New Orleans, USA. About Diamyd Medical Diamyd Medical is a Swedish biopharmaceutical company focusing on the development of pharmaceuticals for the treatment of autoimmune diabetes and its complications. The company"s most advanced project is the GAD-based drug Diamyd(R) for type 1 diabetes. Phase III trials for this drug are in progress in both Europe and the US. In addition, the company has started clinical studies in the US in the area of chronic pain, using its Nerve Targeting Drug Delivery System (NTDDS). The company has also out-licensed the use of GAD for the treatment of Parkinson"s disease. The company has currently three clinical-phase products. Diamyd Medical has offices in Sweden and in the US. Shares are listed on the Nasdaq OMX Nordic Exchange (ticker: DIAM B) and on OTCQX in the US (ticker: DMYDY) administered by the Pink Sheets and the Bank of New York (PAL). This information is disclosed in accordance with the Swedish Securities Markets Act, the Swedish Financial Instruments Trading Act, or the requirements stated in the listing agreements Diamyd Medical AB (publ)


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):